Grace Therapeutics, Inc.
GRCE - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.17M
Close$
$0.73
60.7% downside
Current Fair Value
60.7% downsideOvervalued by 60.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $34.17 Million |
|---|---|
| Enterprise Value | $20.42 Million |
| Earnings per Share | $-0.47 |
| Beta | 0.37 |
| Outstanding Shares | 17,269,986 |
Return
| Return on Equity | -45.47% |
|---|---|
| Return on Assets | -43.78% |
| Return on Invested Capital | -11.51% |
Valuation & Multiples
| P/E Ratio | -1.54 |
|---|---|
| PEG | -0.42 |
| Price to Sales | - |
| Price to Book Ratio | 0.94 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.63 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.13
Consensus analyst estimateRevenue Estimate
$400,000
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.15
Consensus analyst estimateRevenue Estimate
$1.00 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 122.92% |
|---|---|
| Total Calls | 137,600▲ 171.94% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.00%▼ 1.83% |
|---|---|
| Total Invested | $8.80M▼ 55.43% |
| Investors Holding | 37▲ 1.00% |
About Acasti Pharma Inc
5 employees
CEO: Janelle D'Alvise
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental trea...